Dentsply Sirona Announces Repositioning of Byte within Aligner Portfolio
Dentsply Sirona (Nasdaq: XRAY) announced the repositioning of its Byte business model, emphasizing expanded in-person dentist oversight for treatments. The company aims to leverage Byte's direct-to-consumer (DTC) demand generation capabilities, enhance digital customer journey management, and improve customer service and marketing across its aligner portfolio. Dentsply Sirona will not reinstate at-home Byte Aligner Systems and Impression Kits but will continue to support existing non-contraindicated patients. The company will work with regulatory authorities to obtain necessary clearances before any market launch. CEO Simon Campion highlighted the company's commitment to quality, compliance, and broad access to care. Dentsply Sirona will present this strategy at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Presentation materials and a webcast replay will be available on the company's investor website.
Dentsply Sirona (Nasdaq: XRAY) ha annunciato il riposizionamento del proprio modello di business Byte, enfatizzando un maggiore controllo diretto da parte dei dentisti per i trattamenti. L'azienda punta a sfruttare le capacità di generazione di domanda diretta al consumatore (DTC) di Byte, migliorare la gestione del percorso digitale del cliente e potenziare il servizio clienti e il marketing nell'ambito del suo portfolio di allineatori. Dentsply Sirona non ripristinerà i sistemi di allineatori Byte da home e i kit per impronte, ma continuerà a supportare i pazienti esistenti non controindicati. L'azienda collaborerà con le autorità di regolamentazione per ottenere le necessarie approvazioni prima di qualsiasi lancio sul mercato. Il CEO Simon Campion ha sottolineato l'impegno dell'azienda per la qualità, la conformità e l'accesso ampio alle cure. Dentsply Sirona presenterà questa strategia alla 43ª Conferenza Annuale J.P. Morgan Healthcare il 15 gennaio 2025. I materiali della presentazione e una registrazione del webcast saranno disponibili sul sito web per gli investitori dell'azienda.
Dentsply Sirona (Nasdaq: XRAY) anunció el reposicionamiento de su modelo de negocio Byte, enfatizando una mayor supervisión presencial de los dentistas para los tratamientos. La compañía tiene como objetivo aprovechar las capacidades de generación de demanda directa al consumidor (DTC) de Byte, mejorar la gestión del viaje digital del cliente y optimizar el servicio al cliente y el marketing en su portafolio de alineadores. Dentsply Sirona no reinstaurará los sistemas de alineadores Byte para uso doméstico ni los kits de impresión, pero continuará apoyando a los pacientes existentes no contraindicados. La empresa trabajará con las autoridades regulatorias para obtener las autorizaciones necesarias antes de cualquier lanzamiento al mercado. El CEO Simon Campion destacó el compromiso de la compañía con la calidad, el cumplimiento y un acceso amplio a la atención. Dentsply Sirona presentará esta estrategia en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan el 15 de enero de 2025. Los materiales de la presentación y una grabación del webcast estarán disponibles en el sitio web para inversores de la compañía.
Dentsply Sirona (Nasdaq: XRAY)는 치료를 위한 치과 의사의 대면 감독을 확대한다고 강조하며 Byte 비즈니스 모델을 재편성한다고 발표했습니다. 이 회사는 Byte의 소비자 직접 판매(DTC) 수요 생성 기능을 활용하고, 디지털 고객 여정 관리를 개선하며, 그들의 정렬기 포트폴리오 전반에 걸쳐 고객 서비스 및 마케팅을 향상시키는 것을 목표로 하고 있습니다. Dentsply Sirona는 가정용 Byte 정렬기 시스템 및 인상 키트를 재시작하지 않을 것이지만, 기존의 비금기 환자를 계속 지원할 것입니다. 이 회사는 시장 출시 전에 필요한 승인 절차를 얻기 위해 규제 당국과 협력할 것입니다. CEO 사이먼 캠피온은 품질, 준수 및 폭넓은 치료 접근성에 대한 회사의 의지를 강조했습니다. Dentsply Sirona는 2025년 1월 15일에 열리는 제43회 J.P. Morgan 헬스케어 회의에서 이 전략을 발표할 것입니다. 발표 자료와 웹캐스트 다시보기는 회사의 투자자 웹사이트에서 제공될 것입니다.
Dentsply Sirona (Nasdaq: XRAY) a annoncé le repositionnement de son modèle commercial Byte, en mettant l'accent sur une supervision en personne élargie des dentistes pour les traitements. L'entreprise vise à tirer parti des capacités de génération de demande directe aux consommateurs (DTC) de Byte, à améliorer la gestion du parcours client numérique et à perfectionner le service client et le marketing à travers son portefeuille d'aligneurs. Dentsply Sirona ne réintroduira pas les systèmes d'aligneurs Byte à domicile et les kits d'impression, mais continuera de soutenir les patients existants non contra-indiqués. L'entreprise travaillera avec les autorités réglementaires pour obtenir les autorisations nécessaires avant tout lancement sur le marché. Le PDG Simon Campion a souligné l'engagement de l'entreprise envers la qualité, la conformité et l'accès large aux soins. Dentsply Sirona présentera cette stratégie lors de la 43e Conférence Annuelle de Soins de Santé J.P. Morgan le 15 janvier 2025. Les documents de présentation et un replay du webinaire seront disponibles sur le site des investisseurs de l'entreprise.
Dentsply Sirona (Nasdaq: XRAY) hat die Neupositionierung seines Byte-Geschäftsmodells angekündigt, wobei ein verstärkter persönlicher Aufsicht der Zahnärzte bei Behandlungen hervorgehoben wird. Das Unternehmen beabsichtigt, die Direktvertriebsfähigkeiten (DTC) von Byte zu nutzen, das Management der digitalen Kundenreise zu verbessern und den Kundenservice sowie das Marketing in seinem Portfolio von Alignern zu optimieren. Dentsply Sirona wird die Heim-Bit-Aligner-Systeme und Impression-Kits nicht wieder einführen, aber bestehende nicht kontraindizierte Patienten weiterhin unterstützen. Das Unternehmen wird mit den Regulierungsbehörden zusammenarbeiten, um die notwendigen Genehmigungen vor einer Markteinführung zu erhalten. CEO Simon Campion unterstrich das Engagement des Unternehmens für Qualität, Compliance und umfassenden Zugang zu Pflege. Dentsply Sirona wird diese Strategie auf der 43. jährlichen J.P. Morgan Healthcare-Konferenz am 15. Januar 2025 präsentieren. Präsentationsmaterialien und eine Aufzeichnung des Webcasts werden auf der Investorenseite des Unternehmens verfügbar sein.
- Repositioning Byte to include expanded in-person dentist oversight.
- Leveraging Byte's DTC capabilities across the company.
- Enhancing digital customer journey management and customer service.
- Discontinuation of at-home Byte Aligner Systems and Impression Kits.
Insights
The repositioning of Byte within Dentsply Sirona's aligner portfolio marks a strategic pivot away from pure direct-to-consumer aligners towards a hybrid model with increased dental professional oversight. This shift reflects broader industry challenges with DTC aligners and regulatory scrutiny. The decision to not reinstate at-home Byte Aligner Systems while maintaining support for existing patients indicates potential revenue headwinds in the near term.
The move to integrate Byte's DTC capabilities across the company's broader portfolio suggests a more conservative but potentially more sustainable approach to market expansion. By leveraging Byte's digital customer journey management and marketing expertise, Dentsply Sirona aims to enhance its competitive position in the
The timing of this announcement, coinciding with the J.P. Morgan Healthcare Conference, indicates the company's proactive approach to addressing investor concerns about the DTC aligner business model's sustainability. However, the lack of specific financial guidance or timeline for the new business model implementation creates uncertainty around near-term revenue projections.
The carefully worded announcement regarding Byte's repositioning reveals significant regulatory considerations. The statement that Dentsply Sirona "will continue to work with regulatory authorities and obtain any necessary clearances" suggests potential regulatory compliance challenges with the previous direct-to-consumer model. This proactive regulatory alignment strategy reduces legal exposure but may require substantial time and resources to implement.
The commitment to support existing "non-contraindicated" Byte Aligner patients while discontinuing new at-home treatments indicates a risk-mitigation approach that balances patient care obligations with regulatory compliance. This structured wind-down of the current DTC model, while maintaining support for existing patients, helps shield the company from potential liability while transitioning to a new business model.
Company to Present at J.P. Morgan Healthcare Conference
CHARLOTTE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company plans to refocus the Byte business model around treatments that include expanded in-person dentist oversight. The Company is evaluating the go-to-market business and economic model and expects to leverage collaborative direct-to-consumer (“DTC”) demand generation with dentists using Byte core competencies, expand digital customer journey management across the aligner portfolio, and utilize Byte skillsets to further enhance customer service and marketing across the Company. In connection with this review, Dentsply Sirona is not reinstating the at-home Byte Aligner Systems and Impression Kits but will continue to provide support for non-contraindicated Byte Aligner patients currently undergoing treatment. Dentsply Sirona will continue to work with regulatory authorities and obtain any necessary clearances prior to any market launch.
“Our actions demonstrate our continued commitment to quality and compliance in everything we do. With that in mind and consistent with Dentsply Sirona’s goal of providing access to quality care for a broad patient population, we plan to redefine the Byte business model while leveraging their strong capabilities including the DTC engine,” said Simon Campion, President and Chief Executive Officer of Dentsply Sirona. “We believe there is applicability for DTC demand generation in dentistry including aligners and we have already commenced deploying Byte’s strategic capabilities across our Company.”
J.P. Morgan Healthcare Conference
As previously announced, Dentsply Sirona will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 am PT (10:30 am ET). During the presentation, representatives of the Company will present the materials attached to the Company’s Form 8-K that was filed today with the Securities and Exchange Commission (“SEC”). The Company also expects to discuss the Byte announcement as part of that presentation.
Presentation materials and webcast information for the investor conference, including a replay of the webcast following the conference, will be available on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com.
About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solution offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact Information:
Investors:
Andrea Daley
Vice President, Investor Relations
+1-704-591-8631
InvestorRelations@dentsplysirona.com
Forward-Looking Statements and Associated Risks
This Press Release contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including statements and projections concerning the ability to successfully refocus the Byte business or the ability to leverage Byte assets to support other aspects of the Company’s business. The Company’s forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements which speak only as of the date they are made. The forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company’s actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following: the Company’s ability to remain profitable in a very competitive marketplace, which depends upon the Company’s ability to differentiate its products and services from those of competitors; the Company’s failure to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company’s distribution channels for its products and the failure of significant distributors of the Company to effectively manage their inventories; increased regulation that impacts the Company’s business including Byte; the Company’s failure to receive any regulatory authorization needed to commercialize any particular product or service offering; the Company’s ability to control costs and failure to realize expected benefits of cost reduction and restructuring efforts and the Company’s failure to anticipate and appropriately adapt to changes or trends within the rapidly changing dental industry. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in the Company’s most recent Annual Report on Form 10-K, including any amendments thereto, and any updating information which may be contained in the Company’s other filings with the SEC, when reviewing any forward-looking statement. The Company notes these factors for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either the foregoing lists, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties.
FAQ
What changes are being made to Byte's business model by Dentsply Sirona?
How will Byte's capabilities be utilized across Dentsply Sirona?
What will happen to current Byte Aligner patients?
When will Dentsply Sirona present its new Byte strategy?
Where can investors find the presentation materials for Dentsply Sirona's conference?
